ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	5/2/2016 9:26:06 PM
	of 4474

Editorial on recent Lancet article on EPIC trial... "The EPIC trial showed the potential of ponatinib to induce early molecular response, early MR4, and early MR4·5, which are required for treatment-free remission after drug discontinuation. However, with the dose of 45 mg of ponatinib used, the benefits of the drug might not outweigh the risk of developing arterial occlusive events. For this reason, the potential of ponatinib should be evaluated at lower doses even in the first-line setting, with more stringent inclusion criteria to avoid patients with high cardiovascular risk scores." thelancet.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next